Looking forward to your response.
Hesenna has entered into strategic cooperation with a number of domestic and foreign MAHs, and obtained full commercialization rights in China for a number of original high-end products;
The landed projects include Rocaltrol,Rivotril,Carmustine Injection and Auxiton.
Hesenna launched the strategy of “integrated diagnosis and treatment solutions” around products under Pharmanovia, which covers the whole process of bone health management of “diagnosis + treatment + regular follow-up” for osteoporosis and bone metastasis . We continue to introduce high-end products and have reached preliminary project cooperation with Piramal, Patheon, Aurisco, Pharmanovia and Cheplapharm.
In 2020, Zhejiang Hesenna Medicine Co., Ltd. was founded.HSN
has fully responsible for the government affairs, declaration and registration, marketing and promotion of the original research brands Bondronat and Bonviva.
At the end of 2018, the company reached a cooperation with Pharmanovia, and was fully responsible for the marketing promotion strategy of Bondronat in China.
Responding to changes of the pharmaceutical industry, Zhonghai and Hongsen join forces. Conform to the development of the times, took advantage of the strengths to build the original product marketing system.